Small interfering RNA (siRNA)-based targeting breast cancer therapy

Breast cancer (BC) poses a substantial impact on the global health landscape, thereby demanding the creation of novel therapeutic approaches aimed at enhancing patient outcomes. The objective of this article is to conduct an analysis of the potential benefits and drawbacks related to the application of siRNA-based therapy in the context of BC, along with its targeting capabilities. This paper commences by highlighting the imperative need for pioneering treatment methodologies in response to the substantial incidence of BC. This section of the article examines the molecular mechanisms underlying small interfering RNA (siRNA), with a particular emphasis on its role in selectively suppressing cancer-associated genes involved in tumor initiation and progression. The efficacy of therapies utilizing siRNA is reliant on the presence of effective delivery mechanisms. The objective of this research is to examine the effectiveness and safety of liposomes, nanoparticles (specifically carbon nanoparticles and metal nanoparticles), as potential vehicles for delivering targeted siRNA. Moreover, the objective of this article is to investigate the potential of siRNA in the context of mitigating drug resistance and augmenting the effectiveness of treatments. Additionally, the study aims to investigate the obstacles related to delivery efficiency, potential immune responses, and the suppression of off-target genes. The present comprehensive literature review concludes with a meticulous examination of the potential transformative effects of siRNA-based therapeutic approaches for BC. The primary objective of this study is to advance the development of enhanced and personalized therapeutic interventions for BC.